Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.

Rearrangements of the RET receptor tyrosine kinase gene generating RET/PTC oncogenes are specific to papillary thyroid carcinoma (PTC), the most frequent thyroid tumor. Here, we show that the RET/PTC1 oncogene, when exogenously expressed in primary normal human thyrocytes, induces the expression of a large set of genes involved in inflammation and tumor invasion, including those encoding chemokines (CCL2, CCL20, CXCL8, and CXCL12), chemokine receptors (CXCR4), cytokines (IL1B, CSF-1, GM-CSF, and G-CSF), matrix-degrading enzymes (metalloproteases and urokinase-type plasminogen activator and its receptor), and adhesion molecules (L-selectin). This effect is strictly dependent on the presence of the RET/PTC1 Tyr-451 (corresponding to RET Tyr-1062 multidocking site). Selected relevant genes (CCL20, CCL2, CXCL8, CXCR4, L-selectin, GM-CSF, IL1B, MMP9, UPA, and SPP1/OPN) were found up-regulated also in clinical samples of PTC, particularly those characterized by RET/PTC activation, local extrathyroid spread, and lymph node metastases, when compared with normal thyroid tissue or follicular thyroid carcinoma. These results, demonstrating that the RET/PTC1 oncogene activates a proinflammatory program, provide a direct link between a transforming human oncogene, inflammation, and malignant behavior.

[1]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[2]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[3]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[4]  Heiko Müller,et al.  GenePicker: replicate analysis of Affymetrix gene expression microarrays , 2004, Bioinform..

[5]  T. Jørgensen,et al.  Review of thyroid cancer cases among patients with previous benign thyroid disorders. , 2000, Thyroid : official journal of the American Thyroid Association.

[6]  A. Stoppacciaro,et al.  Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis , 2001, The Journal of pathology.

[7]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[8]  D. Bar-Sagi,et al.  Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. , 2004, Cancer cell.

[9]  Ivan Stamenkovic,et al.  Extracellular matrix remodelling: the role of matrix metalloproteinases , 2003, The Journal of pathology.

[10]  P. Allavena,et al.  Hepatocyte Growth Factor (HGF) Stimulates Tumor Cells to Release Chemokines Active in Recruiting Dendritic Cells , 2000 .

[11]  M. Borrello,et al.  RET tyrosine kinase signaling in development and cancer. , 2005, Cytokine & growth factor reviews.

[12]  J. Rosai,et al.  Tumors of the thyroid gland , 1992 .

[13]  B. Aggarwal,et al.  Nuclear factor-kappaB: the enemy within. , 2004, Cancer cell.

[14]  M. Kruhøffer,et al.  Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells , 2004, Oncogene.

[15]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[16]  J A Bond,et al.  Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure. , 1998, The American journal of pathology.

[17]  M. Santoro,et al.  The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[18]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[19]  L. Sobin,et al.  TNM classification of malignant tumors, fifth edition (1997) , 1997, Cancer.

[20]  M. Kruhøffer,et al.  The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. , 2005, The Journal of clinical investigation.

[21]  G. Kollias,et al.  Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis , 1999, Nature Medicine.

[22]  M. Nikiforova,et al.  Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. , 2005, The Journal of clinical investigation.

[23]  Y. Iwakura,et al.  IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Gariboldi,et al.  Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer , 2004, Oncogene.

[25]  J. Sagartz,et al.  Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. , 1996, Endocrinology.

[26]  C Eng,et al.  Gene expression in papillary thyroid carcinoma reveals highly consistent profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[28]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[29]  G. Viglietto,et al.  RET/PTC oncogene activation is an early event in thyroid carcinogenesis. , 1995, Oncogene.

[30]  B. Clarkson.  Retinoic acid in acute promyelocytic leukemia: the promise and the paradox. , 1991, Cancer cells.

[31]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[32]  M. Santoro,et al.  A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases , 1987, Nature.

[33]  M. Pierotti,et al.  RET and NTRK1 proto‐oncogenes in human diseases , 2003, Journal of cellular physiology.

[34]  F. Zunino,et al.  Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. , 2004, Journal of the National Cancer Institute.

[35]  P. Proost,et al.  The role of CD26/DPP IV in chemokine processing. , 1999, Chemical immunology.

[36]  M. Borrello,et al.  Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein , 2001, Oncogene.

[37]  M. Burdick,et al.  Depletion of CXCR2 Inhibits Tumor Growth and Angiogenesis in a Murine Model of Lung Cancer1 , 2004, The Journal of Immunology.

[38]  M. Kruhøffer,et al.  Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas , 2004, Oncogene.

[39]  B. Bauvois.  Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? , 2004, Oncogene.

[40]  M. Santoro,et al.  Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors , 2003, Oncogene.

[41]  I. Weissman,et al.  L-selectin can facilitate metastasis to lymph nodes in a transgenic mouse model of carcinogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.